EUCTR2008-003395-22-SE进行中（未招募）不适用
The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition
GlaxoSmithKline Consumer Healthcare0 个研究点目标入组 120 人开始时间: 2008年7月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects aged 18-60 years inclusive
- •2. Body mass index (BMI): BMI in the range 25.0-34.9 kg/m2
- •3. Waist circumference: Females > 35 and Males > 40
- •a) Normal eating habits, consuming 3 meals/day (breakfast, lunch & dinner)
- •b) Willing to follow a hypocaloric diet during the study to achieve weight loss
- •c) Willing to take a multivitamin for the duration of the study.
- •5. Contraception: Females of childbearing potential practicing an acceptable method of contraception or surgically sterile
- •6. Compliance:
- •a) Understands and is willing, able and likely to comply with all study procedures and restrictions
- •b) Has the ability to swallow dosages in capsule form
- •7. Consent: Demonstrates understanding of study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
- •8. General Health: Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy: Women who are known to be pregnant, have a positive pregnancy test, or who are intending to become pregnant over the duration of the study
- •2. Breast-feeding: Women who are breast-feeding
- •3. Diet/exercise: Currently on a special diet or who cannot fulfill the dietary requirements of the study
- •4. Smoking History:
- •a) Smoking cessation within the past 6 months
- •b) Current smokers
- •5. Allergy/tolerance: Known or suspected intolerance or hypersensitivity to the study materials and study foods (or closely related compounds) or any of their stated ingredients
- •6. Medication:
- •a) Currently taking medication for weight loss or appetite control
- •b) Previous Xenical® (orlistat 120mg) or alli® (orlistat 60mg) use within 3 months of screening date
- •c) Currently taking medication or supplements that influence intestinal transit time and other stool formation parameters or influences cramping (e.g., Anticholinergics, (such as atropine) or cholinergics (such as physostigmine), phenothiazines, tricyclic antidepressants, opiod analgesics (including loperamide), calcium channel antagonists, clonidine, cisapride, octreotide. Also, any laxative or antidiarrheal product)
- •d) Currently taking or withdrawn during the past 6 months any drugs with significant impact on body weight (3.g., serotoninergically acting drugs, antidperssants, central adrenergially acting drugs, drugs inhibiting digestion and absorption, appetite suppressants, metformin)
- •e) Currently taking Cyclosporine, Warfarin or Amiodarone HCl
- •7. Disease/Surgery:
- •a) History of GI disease (e.g., irritable bowel syndrome, diarrhea, inflamed bowel, steatorrhea/fat malabsorption, hemorrhoids, incontinence, pancreatitis)
- •b) History of psychological disorder, including eating disorders such as anorexia nervosa and bulimia
- •c) History of neurological disorder (e.g., seizures, parkinson's disease. Alzheimer's disease)
- •d) History of hypo/hyperthyroidism unless euthyroid and controlled on a stable dose of medication for at least 6 months
- •e) History of surgery for weight loss
- •f) Uncontrolled hypertension
- •g) Heart disease
- •h) Diabetes Mellitus (Type 1 and 2) (Fasting Blood Glucose >126 mg/dL)
- •8. Clinical Study/Experimental Medication:
- •a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit at the start of the study
- •b) Previous participation in this study
- •9. Substance abuse: Subject has a recent history (within the last 2 years) of alcohol or other substance abuse
- •10. Subject has a positive urine drug test for cannabinoids, opiates, amphetamines or cocaine at screening
- •11. Personnel: Subject is an employee of the sponsor or the direct clinical unit, and/or is a friend or family member of an employee of the clinical unit
- •12. Subject has a known history of panic attacks and/or claustrophobia or other conditions precluding safe EchoMRI, CT or other scanning modalities according to local guidelines (e.g., pacemaker, hearing aid, metallic body piercing and/or other metal implants) or in the opinion of the Investigator the subject exceeds size limitations for the instruments
- •13. Subject has had a weight loss or gain of > or = to 3 kg in the 3 months prior to screening
- •14. Subject has had previous radiation exposure within the past year (e.g. diagnostic or medical tests) which, in the opinion of the investigator, would preclude subject participation.
研究者
相似试验
已完成
4 期
Effect of Orlistat in Body CompositionOverweightObesityNCT00752726GlaxoSmithKline131
Unknown
4 期
The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)Polycystic Ovaries SyndromeObesityNCT01475019Aristotle University Of Thessaloniki200
已完成
4 期
Weight Loss Aid in an Exposed PopulationPolybrominated Biphenyl PoisoningNCT03582722Emory University100
招募中
3 期
Effect of Weight Reduction Intervention versus Standard of Care among People Living with HIV Experiencing Significant Weight Gain from Dolutegravir-Based Regimens: RCTTCTR20240818003Faculty of Medicine, CHIANG MAI University58
已完成
2 期
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese SubjectsObesityNCT01126970Shionogi486